Skip to main
ABVX
ABVX logo

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 70%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abivax SA is poised for significant growth due to promising Phase 3 clinical trial results for its drug candidate, obefazimod, which has demonstrated efficacy and safety that align with regulatory expectations. The company's ability to meet co-primary endpoints and its increased peak sales estimates, driven by a refined understanding of market penetration, suggest a multi-billion-dollar revenue potential in addressing chronic inflammatory diseases like ulcerative colitis. Additionally, the rapid therapeutic effect of obefazimod, particularly in refractory patients, underscores its strong value proposition in a market with substantial unmet medical needs.

Bears say

Abivax SA faces significant challenges in translating promising induction trial results for its drug candidate obefazimod into compelling maintenance efficacy, a concern echoing previous failures with similar therapies from other companies. The company has a history of financial losses and lacks a proven path to profitability, which further raises doubts about its market viability, especially given that previous oral therapies have not succeeded in the inflammatory bowel disease sector. Additionally, the risks associated with the drug's efficacy and potential partnership hurdles contribute to an overall negative outlook on its ability to successfully commercialize obefazimod.

Abivax SA (ABVX) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 70% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 10 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.